COMMUNIQUÉS West-GlobeNewswire

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
28/02/2024
Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer Amtagvi Regulatory [...]
WW International, Inc. Announces Fourth Quarter and Full Year 2023 Results
28/02/2024
Fourth Quarter 2023 End of Period Subscribers of 3.8 million, including 67 thousand End of Period Clinical Subscribers Revenues of $206.0 million Gross margin of 60.6%; excluding the net impact of restructuring charges [...]
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
28/02/2024
WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
28/02/2024
LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
28/02/2024
- Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering - - Strong cash position and [...]
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
28/02/2024
BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of [...]
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
28/02/2024
HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 [...]
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
28/02/2024
Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter Net Income was $53 million, Inclusive of a $40 million One-Time Non-Cash Tax Benefit Fourth Quarter Adjusted EBITDA of $ [...]
Vimient Launches Innovative Program With Regency Place Senior Living to Offer Enhanced Senior Care
28/02/2024
Synergistic partnership with Sacramento senior living community will enrich holistic wellness, personalized care and resident safety ROSEVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vimient – a leading provider of [...]
Janssen reçoit un avis favorable de la part du CMUH pour CARVYKTI®▼ (ciltacabtagène autoleucel ; cilta-cel) dans le traitement du myélome multiple en rechute et réfractaire en premières lignes
28/02/2024
Les résultats de l’étude de phase III CARTITUDE-4, qui étayent la recommandation du CMUH, ont démontré que le cilta-cel avait le potentiel d’offrir un bénéfice significatif aux patients en premières lignes de traitement [...]
The Kettle Society Welcomes Wayne Leslie as New Executive Director
28/02/2024
Following a comprehensive search, we are excited to announce the appointment of a new Executive Director with the planned retirement of long-serving ED, Nancy Keough. VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE [...]
Full-year 2023 results
28/02/2024
Ludwig de Mot appointed Chief Executive Officer Strategic Review outcome: launch of the FOCUS-27 project to improve competitiveness and unlock sustainable & profitable growth Full-Year 2023 results: resilience in a [...]
Résultats annuels 2023
28/02/2024
Ludwig de Mot est nommé Directeur général Résultats de la revue stratégique : lancement du projet FOCUS-27 pour améliorer la compétitivité et libérer une croissance durable et rentable Résultats annuels 2023 : [...]
Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to April 3, 2024
28/02/2024
MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock [...]
SAFE - CHIFFRE D’AFFAIRES 2023
28/02/2024
CHIFFRE D’AFFAIRES 2023 Eragny-sur-Oise - France - le 28 février 2024 à 18h . Safe SA (la « Société ») publie son chiffre d’affaires annuel consolidé réalisé sur l’exercice 2023. En k€ 2023* 2022 Variation en % Chiffre [...]
SAFE - MISE A DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2023
28/02/2024
Eragny-sur-Oise - France - le 28 février 2024 à 18h . Safe SA (la « Société ») annonce la publication aujourd’hui de son rapport financier semestriel 2023 et son dépôt auprès de l’Autorité des marchés [...]
RAMSAY SANTE : Half-year results at end of December 2023
28/02/2024
PRESS RELEASE Paris, 28 February 2024 Half-year results at the end of December 2023 As a mission-driven company, Ramsay Santé continues its support for the care of all patients and all pathologies, both in France and in [...]
RAMSAY SANTE : résultats semestriels à fin décembre 2023
28/02/2024
COMMUNIQUÉ DE PRESSE Paris, le 28 février 2024 Résultats semestriels à fin décembre 2023 Entreprise à mission, Ramsay Santé poursuit son soutien pour la prise en charge de tous les patients, et toutes les pathologies, [...]
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
28/02/2024
ANAHEIM, CA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance use and related disorders, [...]

Pages